Literature DB >> 8250609

Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone.

L Martin1, J D Pauls, J P Ryan, M J Fritzler.   

Abstract

OBJECTIVES: The role of autoantibodies in the investigation and management of rheumatic diseases is well recognised. The objective of this study was to determine the clinical significance of the co-occurrence of antibodies to centromere and histone in serum samples from patients investigated for systemic rheumatic diseases.
METHODS: Serum samples from 1316 consecutive patients were screened for antinuclear antibodies and the clinical findings in patients with antibodies to centromere alone were compared with those with antibodies to both centromere and histone.
RESULTS: Twenty six patients had antibodies to centromere. Fourteen patients had antibodies to centromere alone and 12 patients had antibodies to centromere and histone. Four of the 12 patients with antibodies to centromere and histone had diffuse scleroderma with severe pulmonary or vascular disease.
CONCLUSIONS: A subset of patients with scleroderma with antibodies to centromere and histone has been identified retrospectively, who have severe pulmonary or vascular disease. It will be of interest to follow up the clinical course of other patients with scleroderma who have both antibodies for the development of pulmonary or vascular disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250609      PMCID: PMC1005188          DOI: 10.1136/ard.52.11.780

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Purification of the centromere-specific protein CENP-A and demonstration that it is a distinctive histone.

Authors:  D K Palmer; K O'Day; H L Trong; H Charbonneau; R L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

3.  Familial occurrence of progressive systemic sclerosis and systemic lupus erythematosus.

Authors:  R H Flores; M B Stevens; F C Arnett
Journal:  J Rheumatol       Date:  1984-06       Impact factor: 4.666

4.  Commentary: neonatal lupus erythematosus.

Authors:  T T Provost
Journal:  Arch Dermatol       Date:  1983-07

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Antibodies to histones in drug-induced and idiopathic lupus erythematosus.

Authors:  M J Fritzler; E M Tan
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

7.  Autoantibodies directed against sicca syndrome antigens in the neonatal lupus syndrome.

Authors:  H L Franco; W L Weston; C Peebles; S L Forstot; P Phanuphak
Journal:  J Am Acad Dermatol       Date:  1981-01       Impact factor: 11.527

8.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La.

Authors:  C A Wasicek; M Reichlin
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

View more
  3 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 2.  Autoantibodies to components of the mitotic apparatus.

Authors:  J B Rattner; G J Mack; M J Fritzler
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

3.  Antibodies to nuclear antigens in three patients with scleroderma and asthma.

Authors:  K Nikolov; M Baleva; T Vulcheva; P Jakovliev
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.